Prot #SGN35-033: A Phase 2 Study of Brentuximab Vedotin in Combination with Pembrolizumab in Subjects with Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment

Project: Research project

Project Details

StatusActive
Effective start/end date2/11/212/11/24

Funding

  • Seattle Genetics, Inc. (Prot #SGN35-033)